Test Price
2,800 AED✅ Home Collection Available
C19orf12 Gene (SPG43) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين C19orf12 (SPG43) بتقنية التسلسل الجيني المتقدم في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary & Clinical Assurance
- ✔ 99.9% Diagnostic Sensitivity – ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139). الدقة التشخيصية 99.9% – معتمدة وفق معيار ISO 9001:2015
- ✔ Premium Home Collection – ISO Certified Cold-Chain Logistics & VIP Mobile Phlebotomy (8 AM – 11 PM).
- ✔ Telephonic Post-Test Clinical Guidance – Expert interpretation of results with genetic counselling support.
- ✔ Insurance Direct Billing – Verify coverage via WhatsApp +971 54 548 8731.
Clinical Test Overview
The C19orf12 gene NGS test detects pathogenic variants in the C19orf12 gene, confirming autosomal recessive hereditary spastic paraplegia type 43 (SPG43). It utilizes next-generation sequencing for comprehensive single-gene analysis, delivering complete exon coverage with >99% sensitivity. يُقدِّم هذا الاختبار تحليلاً جينياً شاملاً للطفرة المسببة للشلل التشنجي الوراثي من النوع 43 بدقة عالية.
| Feature | Our Single‑Gene NGS Test | Whole Exome Sequencing (WES) |
|---|---|---|
| Methodology | Targeted Next‑Generation Sequencing | Whole Exome Capture & Sequencing |
| Diagnostic Precision | >99.9% analytical sensitivity for C19orf12 | High coverage but dependent on target enrichment; may miss deep intronic variants. |
| Turnaround Time | 3 – 4 Weeks | 6 – 8 Weeks |
| Incidental Findings | None – analysis limited to C19orf12 gene | Risk of secondary/incidental findings outside primary indication. |
Physician Insight & Safety Protocol
— Dr. PRABHAKAR REDDY, DHA License 61713011
⚠ Medication Alert
Do not discontinue any prescribed medication without explicit instruction from your treating physician.
🚨 Safety Exclusion Criteria
- Recent blood transfusion or bone marrow transplant (may interfere with DNA source).
- Inability to provide a sterile blood sample or FTA card due to severe skin condition.
- Non‑consenting minors – genetic testing must comply with UAE CDS Law 2026 (Minors) and parental consent requirements.
Seek emergency care immediately if you experience: sudden loss of mobility, severe muscle spasms, breathing difficulty, or loss of consciousness.
Patient FAQ & Clinical Guidance
1. What is the C19orf12 (SPG43) genetic test and why is it ordered?
This targeted next‑generation sequencing test identifies mutations in the C19orf12 gene, providing a definitive molecular diagnosis for hereditary spastic paraplegia type 43 and informing recurrence risk. يُستخدم هذا الاختبار لتأكيد تشخيص الشلل التشنجي الوراثي من النوع 43 الناتج عن طفرات في جين C19orf12، وتحديد نسبة خطورة تكرار الإصابة في العائلة.
2. How accurate is the NGS test and how should I prepare?
The test demonstrates >99.9% analytical sensitivity for known pathogenic variants within the C19orf12 coding region, requiring only a standard blood draw or dried blood spot card without fasting. تبلغ حساسية هذا الاختبار أكثر من 99.9% في تحديد الطفرات المرضية في جين C19orf12، ويمكن إجراؤه عبر عينة دم بسيطة دون الحاجة للصيام.
3. What happens after the and how will I receive my results?
Results are released within 3–4 weeks via secure electronic delivery, and a complimentary telephonic genetic counselling session is offered to explain the clinical implications. تُسلم النتائج خلال 3 إلى 4 أسابيع بطريقة إلكترونية آمنة، مع جلسة استشارة وراثية هاتفية مجانية لتوضيح الدلالات السريرية.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians